Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024 Nanotech Investing
Sona Nanotech Touts "Superior" Results from Animal Study for Cancer Therapy, Eyes In-human Study Nanotech Investing
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference Nanotech Investing
Sona Appoints Chief Medical Officer and Files Provisional Conjugation Patent Technology Investing News
Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer Nanotech Investing
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results Nanotech Investing
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss Nanotech Investing
